![](https://endpts.com/wp-content/uploads/2021/11/AP_21261593534919-scaled.jpg)
Uğur Şahin, BioNTech CEO (ddp images/Sipa USA/Sipa via AP Images)
BioNTech bets on difficult STING field via small molecule pact with a Polish biotech
BioNTech is beefing up its relatively thin small molecule pipeline by adding weight to a clinically difficult corner of oncology R&D: STING agonists. To do …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.